Cavendish Global Health Impact Forum San Diego 2016

August 22, 2016

Cavendish Global provides family offices and their foundations (from across the world) with a peer-to-peer knowledge expansion and relationship building environment.

Cavendish Global Impact Forums consist of events, panels and discussions where attendees can share insight and establish partnerships on impact investing, grant-giving and sustainable philanthropy projects which they are passionate about.

Cavendish Global Health Impact Forum

The 2016 Cavendish Global Impact Forum was hosted by Biocom in La Jolla, California with keynote speaker, J. Craig Venter, PhD. Venter is regarded as one of the leading scientists of the 21st century for his numerous and invaluable contributions to genomic research. He is founder, chairman, and CEO of the J. Craig Venter Institute; Co-Founder, Executive Chairman and Co-Chief Scientist of Synthetic Genomics Inc; and also a Co-Founder, Executive Chairman and CEO of Human Longevity Inc, a San Diego-based genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span.

This year, I presented with the other notable speakers at the Forum on two panels during the conference: De-Risking Investments in Transformative Innovation, and Evolution of Immunotherapy: Magic Bullets, Moonshots, & Beyond. On the former, I was joined by speakers Barry Didato (CIO of The Innovation Institute), Harrison Perry (Partner at Interprise Partners) and Brian Laden (Co-Founder and Partner at Tristar Health Ventures). On the latter panel, I spoke alongside esteemed Tocagen speakers Lori Kunkel, Harry Gruber and Faheem Hasnain.

Cavendish Global Health Impact Forum 2016 Faheem Hasnain Lori Kunkel Harry Gruber Branden Muhl

Lori Kunkel is a member of the Board of Directors of Tocagen and Loxo Oncology. Dr. Kunkel has over 20 years of experience in oncology and immunology drug development and commercialization. She previously served as Chief Medical Officer of Pharmacyclics (acquired by AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals), which ultimately resulted in the global approvals of cancer therapeutics IMBRVICA® and Kyprolis®, respectively.

Harry Gruber is President and Chief Executive Officer at Tocagen. As one of the pioneers in gene therapy, Dr. Gruber was previously a founder and/or inventor of the underlying technology for the public companies such as Viagene (acquired by Novartis Pharmaceuticals), Gensia (acquired by Teva Pharmaceutical Industries) and Kintera Inc. (acquired by Blackbaud), which achieved a combined value of over $7 billion. He is the author of over 100 original scientific articles and an inventor of over 33 issued and numerous pending patents.

Faheem Hasnain is a distinguished biopharmaceutical industry leader with over 30 years of experience. Mr. Hasnain currently serves as Chairman of the Board of Directors at Tocagen and Kura Oncology. He previously served as President and CEO of Receptos, Inc., which was recently acquired by Celgene Corporation. He has also served as Chairman of the Board of Sente, Inc. and Ambit Biosciences Corporation (acquired by Daiichi Sankyo Company), as well as serving on the Board of Directors for numerous successful companies such as Seragon Pharmaceuticals (acquired by Roche) and Aragon Pharmaceuticals (acquired by Johnson & Johnson).

Truly an intellectual honor and privilege to spend the day with these key players in the biotech industry.

View full video coverage from my panel discussions below:

De-Risking Investments in Transformative Innovation

Evolution of Immunotherapy: Magic Bullets, Moonshots, & Beyond

-Branden Muhl